Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015–2018: A Retrospective Observational Study

Zhou, Yue; Xu, Lina; Wushouer, Haishaerjiang; Yu, Aichen; Xu, Zhenming; Chen, Chaoyang; Cui, Yu Xin; Lu, Qinghong; Guan, Xiaodong; Shi, Luwen

doi:10.3389/fped.2021.679203

Cited by 3 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors reported that H2RAs/PPIs were commonly prescribed (prevalence: 4.4%), PPI use being over two times more frequent than H2RA use (71.9% vs. 28.1%). Unexpectedly, the study's findings showed that H2RAs/PPIs were commonly used (57.5%) in the treatment of infants without digestive system diseases, mostly suffering from respiratory diseases including asthma and acute upper respiratory tract infections ( 37 ).…”

Section: Prescribing Patterns Of Antisecretory Medicationsmentioning

confidence: 99%

Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review

Cuzzolin¹,

Locci²,

Chicconi³

et al. 2023

Transl Pediatr

View full text Add to dashboard Cite

Gastroesophageal reflux (GER) is widespread in the pediatric population, especially in infants under 3 months of life where daily episodes of regurgitation are common (1). Usually, GER resolves spontaneously in 95% of infants within 12-14 months of age (2) and causes few or no symptoms (functional GER), but some children may develop symptomatic gastroesophageal reflux disease (GERD) (3).The disease manifestations are different in children compared to adults and vary considerably by age group,

show abstract

Section: Prescribing Patterns Of Antisecretory Medicationsmentioning

confidence: 99%

Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review

Cuzzolin¹,

Locci²,

Chicconi³

et al. 2023

Transl Pediatr

View full text Add to dashboard Cite

show abstract

“…PPIs are preferred to H2RAs in reducing GERD symptoms in adults [17]. Despite the lack of published data about the efficacy of acid suppressants and increasing worries about their complications, oral PPIs have been increasingly used in infantile (under one year of age) GERD [18,19]. In recent guidelines, a 4-week trial of a PPI or H2RA for infants with symptoms such as unexplained feeding difficulties, bizarre behavior, and unsuitable weight gain, along with significant regurgitation, has been suggested [9].…”

Section: Acid-suppressantsmentioning

confidence: 99%

The Safety and Efficacy of Acid Suppression Therapy in Neonatal GERD

Taheri

2023

IJMRA

View full text Add to dashboard Cite

Gastroesophageal reflux (GER) is a common physiologic process in infants that often resolves with growth and maturation, while gastroesophageal reflux disease (GERD) is a serious and common referral disease in infants and neonates. The first-line treatment for both GER and GERD is conservative therapy. H2RAs and PPIs are the two basic pharmacologic agents in the treatment of GERD in pediatrics and adults. The efficacy of PPIs is higher than that of H2RAs in GERD treatment. There are controversies in the pharmacologic treatment of neonatal GERD, and performing more clinical trials to survey the effect of PPIs and H2RAs and compare them with each other is necessary in this age group. We conducted three different clinical trials to compare the efficacy and safety of ranitidine with omeprazole or lansoprazole in refractory neonatal GERD.

show abstract

“…Proton pump inhibitors (PPIs) are gastric acid-suppressive medication, frequently (over-) prescribed and used in all age-groups [ 1 – 5 ], also during the first years of life [ 6 – 11 ]. Although there is no clear consensus on the indications or duration of use in pediatrics [ 12 ], PPIs are among the most common off-label used medications in infants and young children [ 10 , 13 , 14 ]. The broad range of pediatric and especially neonatal indications include (presumed) gastro-esophageal or laryngopharyngeal reflux, prevention and treatment of stress ulcers, eosinophilic esophagitis and infantile colic [ 12 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort

et al. 2022

View full text Add to dashboard Cite

Background The effects of proton-pump inhibitors (PPIs) on the infant microbiome remain unclear. Swedish pilot cohort study to assess the longitudinal effect of long-term PPI on the infant gut microbiome, including ten newborn infants operated for esophageal atresia exposed to PPIs (mean 57 weeks), compared to healthy one-year-old controls. All children were born vaginally and were otherwise healthy. Within- and between sample diversity of the fecal microbiome was assessed using untargeted whole genome Shotgun metagenomics which sequences all the DNA in the sample and can capture genes rather than a taxonomic fingerprint. Results A longer duration of PPI-use was associated with considerable changes in evenness and high variation on diversity within samples compared to a shorter duration of use. The limited difference between baseline samples and controls suggests that this shift was most likely due to the drug exposure and not the underlying alterations on the microbiome. We found no associations with the number of antibiotic treatment episodes among the PPI-users. Conclusion Prolonged PPI-use may alter the early infant gut microbiome composition, especially those with the most prolonged duration of use.

show abstract

Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015–2018: A Retrospective Observational Study

Cited by 3 publications

References 35 publications

Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review

Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review

The Safety and Efficacy of Acid Suppression Therapy in Neonatal GERD

Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort

Contact Info

Product

Resources

About